Retrospective Study
Copyright ©The Author(s) 2024.
World J Gastroenterol. Oct 7, 2024; 30(37): 4132-4148
Published online Oct 7, 2024. doi: 10.3748/wjg.v30.i37.4132
Figure 1
Figure 1 Flow diagram depicting the patients with infiltrative hepatocellular camrelizumab enrolled in the study. PD1: Programmed cell death protein 1; BMI: Body mass index.